Herreras Julia, Di Maira Tommaso, Vinaixa Carmen, San Juan Fernando, Rubín Ángel, Berenguer Marina
Hepatology and Liver Transplantation Unit and IIS La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Transplant Direct. 2019 Sep 19;5(10):e487. doi: 10.1097/TXD.0000000000000934. eCollection 2019 Oct.
Milan criteria are widely used for liver transplantation selection in hepatocellular carcinoma but have been recognized to be too restrictive. Milan-out criteria are increasingly being adopted. Our aim was to analyze if liver transplantation waitlisted Milan-out hepatocellular carcinoma patients have different outcome than Milan patients.
Retrospective study including all consecutive patients with hepatocellular carcinoma admitted in the waiting list for liver transplantation between January 2012 and January 2015. We included 177 patients, 146 of which eventually transplanted. Downstaging was achieved in the Milan-out cases (n = 29) before waitlisting.
From diagnosis to last follow-up, 29% patients died. Survival at 1 and 5 years from diagnosis was 93% and 75%, respectively in the within Milan group compared with 91% and 61% in the Milan-out group ( = 0.03). Treatment failure occurred in 20% of cases due to tumor progression in the waiting list (44%), death on the waiting list (20%), and hepatocellular carcinoma recurrence postliver transplantation (9%). Milan-out criteria was the only variable predictive of treatment failure remaining in the multivariate analysis with a hazard ratio (HR) of 1.7 (HR, 1.7; 95% confidence interval, 1.34-4.55; = 0.010) and HR of 1.43 (1.23-6.5) in the hepatocellular carcinoma recurrence.
Milan-out criteria are associated with a higher intention-to-treat liver transplantation failure from time of inclusion in the waiting list. However, survival rates are still >50% at 5 years of follow-up.
米兰标准广泛用于肝细胞癌肝移植的选择,但已被认为过于严格。越来越多的人采用米兰外标准。我们的目的是分析等待肝移植的米兰外肝细胞癌患者与米兰标准患者的预后是否不同。
回顾性研究纳入2012年1月至2015年1月期间所有连续列入肝移植等待名单的肝细胞癌患者。我们纳入了177例患者,其中146例最终接受了移植。米兰外病例(n = 29)在列入等待名单前实现了降期。
从诊断到最后一次随访,29%的患者死亡。米兰标准组从诊断起1年和5年的生存率分别为93%和75%,而米兰外组为91%和61%(P = 0.03)。20%的病例出现治疗失败,原因包括等待名单上肿瘤进展(44%)、等待名单上死亡(20%)和肝移植后肝细胞癌复发(9%)。米兰外标准是多变量分析中唯一预测治疗失败的变量,风险比(HR)为1.7(HR,1.7;95%置信区间,1.34 - 4.55;P = 0.010),肝细胞癌复发时的HR为1.43(1.23 - 6.5)。
米兰外标准与从列入等待名单时起意向性治疗肝移植失败率较高相关。然而,随访5年时生存率仍>50%。